{"id":20156,"date":"2023-03-31T23:48:00","date_gmt":"2023-03-31T15:48:00","guid":{"rendered":"https:\/\/flcube.com\/?p=20156"},"modified":"2024-12-28T23:50:24","modified_gmt":"2024-12-28T15:50:24","slug":"everest-medicines-reports-2022-revenue-growth-and-pipeline-updates","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20156","title":{"rendered":"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates"},"content":{"rendered":"\n

China-based Everest Medicines (HKG: 1952<\/a>) has released its financial report for 2022, along with key business updates. The company reported revenues of RMB 12.8 million (USD 1.86 million) for the year ending 31 December 2022, an increase of RMB 12.7 million (USD 1.84 million) compared to the previous year, primarily attributed to the sales of eravacyline and Trodelvy in Singapore. Research and development (R&D) expenses for the year rose by 32% year-on-year (YOY) to RMB 809.7 million (USD 117.8 million), an increase of RMB 196.3 million (USD 28.5 million). Net losses for the year were significantly reduced to RMB 247.3 million (USD 35.98 million), down from RMB 1 billion (USD 145.5 million) in the previous year. As of 31 December 2022, cash and cash equivalents and bank deposits stood at RMB 1.651 billion (USD 240.25 million).<\/p>\n\n\n\n

Product Approvals and Regulatory Updates<\/strong>
During the period, Xerava (eravacycline) received marketing approval in Hong Kong and Singapore for the treatment of complicated intra-abdominal infections (cIAI), with a market filing under review in Taiwan. In 2023, China\u2019s National Medical Products Administration (NMPA) approved its New Drug Application (NDA) for Xerava for the treatment of cIAI in adult patients. Nefecon, which holds breakthrough therapy designation and priority review statuses, is awaiting regulatory decisions in mainland China and is expected to obtain approval later this year. It is also under fast-track review in South Korea and Taiwan.<\/p>\n\n\n\n

License Agreements and Rights Transitions<\/strong>
Everest Medicines returned the rights to develop and commercialize Trodelvy (sacituzumab govitecan) in Greater China and certain Asian markets to Immunomedics Inc., now owned by Gilead. The company also expanded its existing license agreement with Calliditas for Nefecon as a treatment for primary IgAN in South Korea, building on an earlier deal that granted rights in Greater China and Singapore.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[126,27,1164],"class_list":["post-20156","post","type-post","status-publish","format-standard","hentry","category-company","tag-everest-medicines","tag-finanical-reports","tag-hkg-1952"],"yoast_head":"\nEverest Medicines Reports 2022 Revenue Growth and Pipeline Updates - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key business updates. The company reported revenues of RMB 12.8 million (USD 1.86 million) for the year ending 31 December 2022, an increase of RMB 12.7 million (USD 1.84 million) compared to the previous year, primarily attributed to the sales of eravacyline and Trodelvy in Singapore. Research and development (R&D) expenses for the year rose by 32% year-on-year (YOY) to RMB 809.7 million (USD 117.8 million), an increase of RMB 196.3 million (USD 28.5 million). Net losses for the year were significantly reduced to RMB 247.3 million (USD 35.98 million), down from RMB 1 billion (USD 145.5 million) in the previous year. As of 31 December 2022, cash and cash equivalents and bank deposits stood at RMB 1.651 billion (USD 240.25 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20156\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20156\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-31T15:48:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-28T15:50:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20156#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20156\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates\",\"datePublished\":\"2023-03-31T15:48:00+00:00\",\"dateModified\":\"2024-12-28T15:50:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20156\"},\"wordCount\":289,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Everest Medicines\",\"Finanical Reports\",\"HKG: 1952\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20156#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20156\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20156\",\"name\":\"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-31T15:48:00+00:00\",\"dateModified\":\"2024-12-28T15:50:24+00:00\",\"description\":\"China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key business updates. The company reported revenues of RMB 12.8 million (USD 1.86 million) for the year ending 31 December 2022, an increase of RMB 12.7 million (USD 1.84 million) compared to the previous year, primarily attributed to the sales of eravacyline and Trodelvy in Singapore. Research and development (R&D) expenses for the year rose by 32% year-on-year (YOY) to RMB 809.7 million (USD 117.8 million), an increase of RMB 196.3 million (USD 28.5 million). Net losses for the year were significantly reduced to RMB 247.3 million (USD 35.98 million), down from RMB 1 billion (USD 145.5 million) in the previous year. As of 31 December 2022, cash and cash equivalents and bank deposits stood at RMB 1.651 billion (USD 240.25 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20156#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20156\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20156#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates - Insight, China's Pharmaceutical Industry","description":"China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key business updates. The company reported revenues of RMB 12.8 million (USD 1.86 million) for the year ending 31 December 2022, an increase of RMB 12.7 million (USD 1.84 million) compared to the previous year, primarily attributed to the sales of eravacyline and Trodelvy in Singapore. Research and development (R&D) expenses for the year rose by 32% year-on-year (YOY) to RMB 809.7 million (USD 117.8 million), an increase of RMB 196.3 million (USD 28.5 million). Net losses for the year were significantly reduced to RMB 247.3 million (USD 35.98 million), down from RMB 1 billion (USD 145.5 million) in the previous year. As of 31 December 2022, cash and cash equivalents and bank deposits stood at RMB 1.651 billion (USD 240.25 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20156","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=20156","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-31T15:48:00+00:00","article_modified_time":"2024-12-28T15:50:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20156#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20156"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates","datePublished":"2023-03-31T15:48:00+00:00","dateModified":"2024-12-28T15:50:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20156"},"wordCount":289,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Everest Medicines","Finanical Reports","HKG: 1952"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20156#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20156","url":"https:\/\/flcube.com\/?p=20156","name":"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-31T15:48:00+00:00","dateModified":"2024-12-28T15:50:24+00:00","description":"China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key business updates. The company reported revenues of RMB 12.8 million (USD 1.86 million) for the year ending 31 December 2022, an increase of RMB 12.7 million (USD 1.84 million) compared to the previous year, primarily attributed to the sales of eravacyline and Trodelvy in Singapore. Research and development (R&D) expenses for the year rose by 32% year-on-year (YOY) to RMB 809.7 million (USD 117.8 million), an increase of RMB 196.3 million (USD 28.5 million). Net losses for the year were significantly reduced to RMB 247.3 million (USD 35.98 million), down from RMB 1 billion (USD 145.5 million) in the previous year. As of 31 December 2022, cash and cash equivalents and bank deposits stood at RMB 1.651 billion (USD 240.25 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20156#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20156"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20156#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20156"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20156\/revisions"}],"predecessor-version":[{"id":20157,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20156\/revisions\/20157"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}